Orellana Esteban A, Kasinski Andrea L
Department of Biological Sciences, Bindley Bioscience Center, Purdue University, 1203 West State Street, West Lafayette, IN 47907, USA.
Purdue University Interdisciplinary Life Science Program (PULSe), West Lafayette, IN 47907, USA.
Cancers (Basel). 2015 Jul 27;7(3):1388-405. doi: 10.3390/cancers7030842.
Recent progress in microRNA (miRNA) therapeutics has been strongly dependent on multiple seminal discoveries in the area of miRNA biology during the past two decades. In this review, we focus on the historical discoveries that collectively led to transitioning miRNAs into the clinic. We highlight the pivotal studies that identified the first miRNAs in Caenorhabditis elegans to the more recent reports that have fueled the quest to understand the use of miRNAs as markers for cancer diagnosis and prognosis. In addition, we provide insights as to how unraveling basic miRNA biology has provided a solid foundation for advancing miRNAs, such as miR-34a, therapeutically. We conclude with a brief examination of the current challenges that still need to be addressed to accelerate the path of miRNAs to the clinic: including delivery vehicles, miRNA- and delivery-associated toxicity, dosage, and off target effects.
在过去二十年中,微小RNA(miRNA)治疗学的最新进展在很大程度上依赖于miRNA生物学领域的多项开创性发现。在本综述中,我们聚焦于那些共同促使miRNA进入临床应用的历史性发现。我们着重介绍了从在秀丽隐杆线虫中鉴定出首个miRNA的关键研究,到推动将miRNA用作癌症诊断和预后标志物探索的最新报告。此外,我们还深入探讨了揭示miRNA基础生物学如何为推进miRNA(如miR-34a)的治疗应用奠定坚实基础。我们最后简要审视了当前仍需解决的挑战,以加速miRNA进入临床的进程,这些挑战包括递送载体、与miRNA和递送相关的毒性、剂量以及脱靶效应。